top
Search terms
Results 11 - 20 of 37 - ordered by :
Pages: 1 2 3 4
Ehjournal

Based on the analysis of adjusted mortality results of all 19 studies comprising 326 426 patients, digoxin use was associated with an increased relative risk of all-cause mortality [Hazard ratio (HR) ...

European Heart Journal, Vamos, Mate, Erath, Julia W., Hohnloser, Stefan H.

Date : 21/07/2015
Ehjournal

Abstract Aims VENTURE-AF is the first prospective randomized trial of uninterrupted rivaroxaban and vitamin K antagonists (VKAs) in patients with non-valvular atrial fibrillation (NVAF) undergoing ...

European Heart Journal, Cappato, Riccardo, Marchlinski, Francis E., Hohnloser, Stefan H., Naccarelli, Gerald V., Xiang, Jim, Wilber, David J., Ma, Chang-Sheng, Hess, Susanne, Wells, Darryl S., Juang, ...

Date : 21/07/2015 Item size : 303748 bytes
Ehjournal

Large randomized clinical trials and subsequent meta-analyses have clearly demonstrated that these agents have at least comparable if not superior efficacy and cause no more or even less major ...

European Heart Journal, Hohnloser, Stefan H., Lopes, Renato D.

Date : 14/12/2014
Ehjournal

[...]there are persuasive data indicating that AF complicating AMI not only increases the risk for ischaemic stroke during hospitalization but also during follow-up. Introduction Atrial fibrillation ...

European Heart Journal, Schmitt, Joern, Duray, Gabor, Gersh, Bernard J., Hohnloser, Stefan H.

Date : 01/05/2009 Item size : 323928 bytes
Ehjournal

Whereas it is well appreciated that stroke risk in end-stage renal disease is elevated,4 the issue of AF-associated thrombo-embolic risk is more controversial in patients with CKD not on renal ...

European Heart Journal, Hohnloser, Stefan H., Connolly, Stuart J.

Date : 01/10/2011
Ehjournal

Methods and results Patients with AF and more than one risk factor for stroke were randomized to one of three blinded doses of betrixaban (40, 60, or 80 mg once daily) or unblinded warfarin, adjusted ...

European Heart Journal, Connolly, Stuart J., Eikelboom, John, Dorian, Paul, Hohnloser, Stefan H., Gretler, Daniel D., Sinha, Uma, Ezekowitz, Michael D.

Date : 21/05/2013
Ehjournal

Aims X-VeRT is the first prospective randomized trial of a novel oral anticoagulant in patients with atrial fibrillation undergoing elective cardioversion. Methods and results We assigned 1504 ...

European Heart Journal, Cappato, Riccardo, Ezekowitz, Michael D., Klein, Allan L., Camm, A. John, Ma, Chang-Sheng, Le Heuzey, Jean-Yves, Talajic, Mario, Scanavacca, Maurício, Vardas, Panos E., ...

Date : 14/12/2014 Item size : 278462 bytes
Ehjournal

Beneficial effects of ACE-inhibitors on mortality and morbidity in CHF patients were demonstrated in early clinical trials.2,3 ACE-inhibition also diminishes ventricular arrhythmias after myocardial ...

European Heart Journal, Ehrlich, Joachim R., Hohnloser, Stefan H., Nattel, Stanley

Date : 01/03/2006 Item size : 210630 bytes
Ehjournal

Guidelines, Atrial fibrillation, Anticoagulation, Vitamin K antagonists, Non-vitamin K antagonist oral anticoagulants, Left atrial appendage occlusion, Rate control, Cardioversion, Rhythm control, ...

European Heart Journal, Kirchhof, Paulus, Benussi, Stefano, Kotecha, Dipak, Ahlsson, Anders, Atar, Dan, Casadei, Barbara, Castella, Manuel, Diener, Hans-Christoph, Heidbuchel, Hein, Hendriks, Jeroen, ...

Date : 07/10/2016
Ehjournal

In the second of a two-part review, we discuss the use of NOAC for stroke prevention in the following subgroups of patients with AF: (vii) secondary stroke prevention in patients after stroke or ...

European Heart Journal, Diener, Hans-Christoph, Aisenberg, James, Ansell, Jack, Atar, Dan, Breithardt, Günter, Eikelboom, John, Ezekowitz, Michael D., Granger, Christopher B., Halperin, Jonathan ...

Date : 21/03/2017